Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges
| Autor: | Hong Zhao, Qi Wang, Changling Luo, Ligai Liu, Wen Xie |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Liver Cirrhosis
medicine.medical_specialty Cirrhosis Review Article Gastroenterology Antiviral Agents General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Hepatitis B Chronic Chronic hepatitis Internal medicine Medicine Humans Decompensation Antiviral treatment Research data General Immunology and Microbiology business.industry General Medicine Hepatitis B medicine.disease 030220 oncology & carcinogenesis Hepatocellular carcinoma 030211 gastroenterology & hepatology business |
| Zdroj: | BioMed Research International BioMed Research International, Vol 2020 (2020) |
| ISSN: | 2314-6141 2314-6133 |
| Popis: | Liver-function decompensation or hepatocellular carcinoma (HCC) gradually appears after chronic hepatitis B progresses to cirrhosis. Effective antiviral treatment can significantly improve the long-term prognosis of decompensated patients, and some patients present recompensation of decompensated hepatitis B cirrhosis. At present, there are limited research data on the recompensation of decompensated hepatitis B cirrhosis. There is still controversy regarding the evaluation time, evaluation indicators, influencing factors, and long-term prognosis of recompensation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |